WDGMC
5.4.2022 08:47:12 CEST | Business Wire | Press release
Wits University Donald Gordon Medical Centre announced novel study results indicating for the first time that Ultraviolet (UV) room decontamination technology paired with manual cleaning protocols decreased the transmission of Carbapenem-resistant Enterobacterales (CRE) by 23% in a hospital setting. The study results have been published in the March 2022 issue of The Journal of Hospital Infection.
The team of researchers at Wits Donald Gordon Medical Centre (WDGMC), the first private teaching hospital in South Africa, demonstrated the reduction in CRE transmission following a 26-month study and the sustained use of a UV room decontamination device (UVDI-360 Room Sanitizer, provided by US-based manufacturer UVDI and eHealthGroup Infection Control) as an adjunct to standard cleaning, including the use of bleach and quaternary ammonium disinfectants, across the 210-bed hospital. The intervention included broad UV room decontamination across five high-risk patient units (including critical care, oncology, transplant and gastrointestinal surgery rooms) during a 12-month period following a 12-month baseline and two-month, wash-in period.
“Our team’s study indicated that enhanced environmental hygiene utilizing UV room decontamination technology in the hospital can help prevent the transmission of Carbapenem-resistant Enterobacterales , an especially challenging set of multidrug-resistant organisms,” stated lead investigator Dr. Warren Lowman, Clinical Microbiologist & Infection Prevention and Control Specialist, Wits Donald Gordon Medical Centre.
The UV room decontamination device was implemented in three usage scenarios: terminal cleaning following patient discharge, terminal cleaning following patient transfer and, in a novel treatment, occupied rooms where the patient had an existing MDRO infection and was moved during device use. For each scenario, the UV device was operated with five-minute treatment cycles, the number of which varied per room setting and size.
CRE refers to a broader set of microorganisms that demonstrate resistance to at least one of the Carbapenem antibiotics.1 Recent published surveillance studies in South Africa have indicated a CRE infection crude mortality rate of nearly 40%.2
“This research underlines WDGMC’s steadfast commitment to patient and staff safety through the use of novel infection prevention protocols,” said Dr. Sue Tager, Chief Executive Officer, Wits Donald Gordon Medical Centre. “In the ongoing fight to prevent the transmission of superbugs, both in and beyond Africa, these results provide hope and concrete proof that effective solutions exist.”
About Wits Donald Gordon Medical Centre
Wits Donald Gordon Medical Centre (WDGMC) is the first and only private teaching hospital in South Africa. It was established in 2002 when the University of the Witwatersrand (Wits University) bought the Kenridge Hospital with a founding donation from the Donald Gordon Foundation. The institution was then renamed the Wits Donald Gordon Medical Centre. The 210-bed facility’s main specialties are transplant surgery, oncology (paediatric and adult), gastroenterology (medical and surgical), geriatric medicine, interventional radiology ophthalmology, ear-nose and throat, urology, nephrology, cardiology, women’s health and orthopaedics.
___________
1
https://www.cdc.gov/hai/organisms/cre/technical-info.html
2
Perovic O, Ismail H, Quan V, Bamford C, Nana T, Chibabhai V, Bhola P, Ramjathan P, Swe Swe-Han K, Wadula J, Whitelaw A, Smith M, Mbelle N, Singh-Moodley A; for GERMS-SA. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1287-1294. doi: 10.1007/s10096-020-03845-4. Epub 2020 Mar 2. PMID: 32124106.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404006042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom